explore -WSS

explore

author：leisure time 2025-10-04 11:34:08 - browse：56341

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Ebola vaccine can save some who are already sick, per new study

leisure time

WSS

For AI in health care standards, federal regulators join with industry group

Change Healthcare: What is it, why does its cyberattack matter?

ACIP vaccine advisory panel sees its vacancies filled

Resistance to opioid

Congress must protect the remaining independent doctors

Why Eli Lilly’s earnings didn’t quite live up to the hype

focus

explore

hotspot

Jerome Adams on the need for new antivirals for Covid

Microsoft's Peter Lee: Generative AI could help doctors be more human

BioMarin wins approval for gene therapy to treat hemophilia A

The untold story of TV’s first prescription drug ad

United colonoscopy coverage change 'may cost lives,' doctors say

Pregnant women don't need prenatal multivitamins, study concludes

The high cost of giving birth even with insurance

Tome Biosciences co

Hepatitis C has a cure — but many Americans still lack access to it

He's 19 months old and has one of the world’s rarest diseases

hotspot

A new approach to psychiatric drug development

Change Healthcare: What is it, why does its cyberattack matter?

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

First over

Having children helps parents live longer, especially after age 80

Stem cell biologist probes earliest stages of human development

leisure time

leisure time

entertainment

hotspot